By: Adam Feuerstein | 05/12/14 - 06:24 PM EDT
Telik never recovered from hiding the premature deaths of ovarian cancer patients treated with its experimental drug Telcyta. Following the serious ethical lapse in 2007, Telik became a biotech pariah, ignored by scientists and investors. Telik's top executives, the husband-and-wife team Michael Wick and Gail Brown, spent the next seven years cashing paychecks paid for by long-gone shareholders.
With the money finally gone, Telik is also disappearing. On Monday, the company announced a reverse merger with privately held Mabvax Therapeutics. When the deal closes, MabVax stockholders will own 85% of the combined companies, which will also be run by MabVax management and retain the MabVax name. Telik shareholders will own 15% and Wick keeps a seat on the board.
MabVax is developing cancer vaccines, with two products targeting sarcoma and ovarian cancer enrolling patients in proof-of-concept phase II studies.
08/26/14 - 07:00 AM EDT
08/25/14 - 08:48 AM EDT
08/21/14 - 10:23 AM EDT
08/14/14 - 10:20 AM EDT
08/13/14 - 12:04 PM EDT
08/27/14 - 11:32 AM EDT
08/26/14 - 14:30 PM EDT
08/26/14 - 11:34 AM EDT
08/25/14 - 11:41 AM EDT
08/25/14 - 11:09 AM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.